CRMP1/2 expression and phosphorylation has been proposed as a biomarker for several neuropsychiatric pathologies including Alzheimer disease, schizophrenia, and epilepsy [36]. The gene discussed is CRMP1; the disease is early-onset autosomal dominant Alzheimer disease.